Trident neuropsychiatric pains seriously affect the normal working and even life confidence of patients, with a high incidence of trident neuropsychiatric pains, which are more prevalent among women after 40 years of age, at about 50.1 million. The trident nerve pain, called “the first pain in the world”, is a pain in the face caused by the discharge, the cut of the knife, the brushing of the teeth, the washing of the face, the talking, and even the siping of the mouth, which causes pain, which takes seconds or minutes.
Traditional drugs for trident neuropsychiatric pain are currently mainly anti-eclampsia drugs, with more evidence-based research in the country. For the recent effects of tridental treatments in Ramo and Camasipine, a new generation of epilepsy drug Ramo monopharmaceutical treatments have some degree of efficacy and less adverse effects, but their long-term, integrated treatments have good effects in Kamasipine.
A common drug for trident nerve pain.
The usual drug, Qamasipin, should be taken at a minimum dose, starting at a rate of 0.1 g per day and two times per day; if pain relief is minimal, it can be increased by 0.1 to 0.2 g per day every second day after the following day, until pain relief is achieved, with maintenance of 0.4 to 0.8 g per day, with a maximum of 1.2 g per day and a specific dose to be carried out under the direction of a doctor.
Okassipine dosages 300 mg/day, 2 times a day. Usage: Increased until pain is reduced gradually, effective maintenance 600-1200 mg/day, maximum dose at 1800 mg/d for 4-12 weeks, stop if symptoms such as dizziness and vomiting affect normal life.
Sodium acetate: initial dosage 0.4g three times a day, after pain has been reduced, then the 14d will continue and then be reduced as appropriate until it is completely eliminated.
Lamorium: 25 mg per day, plus 25 mg per day between 3 and 7 days, to maintain 300-400 mg/day.
Sodium benzo-p-mg: 100 mg for first use, in two oral doses, which can slowly increase to 30-60 mg/day and maintain a dose of 300-500 mg/day.
PV: 200-300 mg/day, 1 000-4000 mg/day, 1 day, depending on the condition, 300 mg/day, 300 mg/day, with a gradual increase of 300 mg/day, if sustained, to 1800 mg/day.
Persons with trident neuropsychiatric pain are treated through drug-standardized treatment, with the maximum dose being left uncontrollable, and must not be over-dependent on medication and overdose, leading to other complications, at which point they need to resort to microvascular repressure to treat the cause.
